Lilly has for more than 85 years been a worldwide leader in diabetes care. Based in Indianapolis, USA, Lilly introduced the world’s first commercial insulin in 1923 and remains at the forefront of pharmaceutical and delivery-device innovation to manage diabetes. Lilly Diabetes is Lilly’s integrated and global business dedicated to providing personal solutions for everyday life for people who live with and treat diabetes. To achieve the mission of curing diabetes, Lilly and JDRF invite applications from single non-profit institutions or groups of such institutions from Europe and associated countries by issuing this RFA, which indicates joint funding as well as areas of research emphasis. Research will be supported through the award of grants, each of up to € 100,000. As the deadline is 10 working days away, we are reaching out to see if your fellows or junior faculty are interested. The details can be perused at: Lilly Diabetes Grant
Thanks,
Trialect Support
+1.805.850.6002(USA)
Support@trialect.com
Disclaimer: Trialect Inc. is a United States Incorporation, which posts grants, courses, fellowships, clinical trials, medical tourism and partnership opportunities exclusively for health professionals in industry and academia. While Trialect partners with various non-profits and pharmaceutical companies, we are in no way affiliated with, maintained, sponsored or endorsed by any of them including Eli Lilly. Please feel free to copy and paste